Update on the epidemiology of gastro oesophageal reflux disease a systematic review

Log in to MyKarger to check if you already have access to this content.

Buy

• FullText & PDF
• Unlimited re-access via MyKarger
• Unrestricted printing, no saving restrictions for personal use

read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle [KAB] and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve

• Unlimited fulltext viewing Of this article
• Organize, annotate And mark up articles
• Printing And downloading restrictions apply

Select

Subscribe

• Access to all articles of the subscribed year[s] guaranteed for 5 years
• Unlimited re-access via Subscriber Login or MyKarger
• Unrestricted printing, no saving restrictions for personal use

read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: October 23, 2021
Accepted: July 24, 2022
Published online: August 16, 2022

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 1

ISSN: 0257-2753 [Print]
eISSN: 1421-9875 [Online]

For additional information: //www.karger.com/DDI

Abstract

Background: The global pooled prevalence of gastroesophageal reflux disease [GORD] is approximately 14% and varies significantly according to the country. More population-based studies are needed in regions lacking epidemiological data on the prevalence of GORD, such as Eastern Europe, particularly Bulgaria. This current study aimed to evaluate the prevalence of GORD in Bulgaria and assess the risk factors associated with this disorder. Methods: An internet-based health survey was sent to Bulgarian adults. Individuals were invited to complete an online questionnaire on general and gastrointestinal health. The aim of the study was not explicitly stated. The survey collected data on sociodemographic and behavioral characteristics, validated questions to assess GORD, diagnostic questions based on Rome IV criteria to assess irritable bowel syndrome [IBS] and functional dyspepsia [FD], and questions about antisecretory drugs usage. Results: Data were collected from 1,896 individuals [mean age = 35.5 years, SD = 11.7, 73.1% females]. The prevalence of GORD in the study population was 27.5%, while 57.29% of all GORD patients taking PPIs had PPI-refractory GORD. Age [p = 0.02], body mass index [BMI] [p < 0.001], marital status [p = 0.03], occupation [p < 0.001], sexual problems [p < 0.001], FD [p < 0.001], and IBS [p < 0.001] were significantly associated with GORD prevalence. Patients with FD [p < 0.001; OR 5.38], IBS [p = 0.03; OR 1.07], and with higher BMI [p < 0.001, OR 1.05] were at an increased risk of having GORD. Conclusions: The first data on GORD prevalence in the adult population in Bulgaria have been reported. Disorders of gut-brain interaction have a significant impact on the prevalence of GORD.

© 2022 S. Karger AG, Basel

References

1. Clarrett DM, Hachem C. Gastroesophageal reflux disease [GERD]. Mo Med. 2018;115[3]:214–8.
2. Nirwan JS, Hasan SS, Babar ZUD, Conway BR, Ghori MU. Global prevalence and risk factors of Gastro-oesophageal reflux disease [GORD]: systematic review with meta-analysis. Sci Rep. 2020;10[1]:5814.
3. Antunes C, Aleem A, Curtis SA. Gastroesophageal reflux disease. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2021 Jul 18.
4. Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal reflux disease: a review. JAMA. 2020 Dec 22;324[24]:2536–47.
5. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug;101[8]:1900–20; quiz 1943.
6. Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016;150[6]:1257–61.
7. Nakov R, Dimitrova-Yurukova D, Snegarova V, Uzunova M, Lyutakov I, Ivanova M, et al. Prevalence of irritable bowel syndrome, functional dyspepsia and their overlap in bulgaria: a population-based study. J Gastrointestin Liver Dis. 2020 Sep 9;29[3]:329–38.
8. Nakov R, Dimitrova-Yurukova D, Snegarova V, Nakov V, Fox M, Heinrich H. Increased prevalence of gastrointestinal symptoms and disorders of gut-brain interaction during the COVID-19 pandemic: an internet-based survey. Neurogastroenterol Motil. 2022;34[2]:e14197.
9. Aziz I, Palsson OS, Törnblom H, Sperber AD, Whitehead WE, Simrén M. The prevalence and impact of overlapping Rome IV-diagnosed functional gastrointestinal disorders on somatization, quality of life, and healthcare utilization:a cross-sectional general population study in three countries. Am J Gastroenterol. 2018;113[1]:86–96.
10. Radev R. Decree No. 163 for the holding of local elections on 27 October 2019. Bulgarian: Bulgaria: State Gazette; 2019: 56; p. 13.
11. Yuen E, Romney M, Toner RW, Cobb NM, Katz PO, Spodik M, et al. Prevalence, knowledge and care patterns for gastro-oesophageal reflux disease in United States minority populations. Aliment Pharmacol Ther. 2010 Sep;32[5]:645–54.
12. Bor S, Lazebnik LB, Kitapcioglu G, Manannikof I, Vasiliev Y. Prevalence of gastroesophageal reflux disease in Moscow. Dis Esophagus. 2016 Feb–Mar;29[2]:159–65.
13. Chiocca JC, Olmos JA, Salis GB, Soifer LO, Higa R; Argentinean Gastro-Oesophageal Reflux Study Group. et al. Prevalence, clinical spectrum and atypical symptoms of gastro-oesophageal reflux in Argentina: a nationwide population-based study. Aliment Pharmacol Ther. 2005 Aug 15;22[4]:331–42.
14. Bor S, Kitapcioglu G, Kasap E. Prevalence of gastroesophageal reflux disease in a country with a high occurrence of Helicobacter pylori. World J Gastroenterol. 2017;23[3]:525–32.
15. Delshad SD, Almario CV, Chey WD, Spiegel BMR. Prevalence of gastroesophageal reflux disease and proton pump inhibitor-refractory symptoms. Gastroenterology. 2020 Apr;158[5]:1250–61.e2.
16. He J, Ma X, Zhao Y, Wang R, Yan X, Yan H, et al. A population-based survey of the epidemiology of symptomdefined gastroesophageal reflux disease: the systematic investigation of gastrointestinal diseases in China. BMC Gastroenterol. 2010;10:94.
17. Ohara S, Kawano T, Kusano M, Kouzu T. Survey on the prevalence of GERD and FD based on the montreal definition and the Rome III criteria among patients presenting with epigastric symptoms in Japan. J Gastroenterol. 2011;46[5]:603–11.
18. Terano A. The current status of GERD between the west and the east. J Gastroenterol. 2003;38[Suppl 15]:1–2.
19. Ho KY, Cheung TK, Wong BC. Gastroesophageal reflux disease in Asian countries: disorder of nature or nurture?. J Gastroenterol Hepatol. 2006;21[9]:1362–5.
20. Bonatti H, Achem SR, Hinder RA. Impact of changing epidemiology of gastroesophageal reflux disease on its diagnosis and treatment. J Gastrointest Surg. 2008;12[2]:373–81.
21. Fock KM, Poh CH. Gastroesophageal reflux disease. J Gastroenterol. 2010;45[8]:808–15.
22. Flook N, Jones R, Vakil N. Approach to gastroesophageal reflux disease in primary care: putting the montreal definition into practice. Can Fam Physician. 2008;54:701–5.
23. Hung CS, Lee CL, Yang JN, Liao PT, Tu TC, Chen TK, et al. Clinical application of Carlsson’s questionnaire to predict erosive GERD among healthy Chinese. J Gastroenterol Hepatol. 2005;20[12]:1900–5.
24. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastrooesophageal reflux disease: a systematic review. Gut. 2014;63[6]:871–80.
25. Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol. 2006 Nov;101[11]:2619–28.
26. Bor S. Worldwide epidemiology of gastroesophageal disease. In: WGO handbook on heartburn: a global perspective. World Dig Health Day; 2015. p. 12–4.
27. Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Talley NJ. Overlap of dyspepsia and gastroesophageal reflux in the general population: one disease or distinct entities? Neurogastroenterol Motil. 2012;24[3]:229–34, e106.
28. de Bortoli N, Tolone S, Frazzoni M, Martinucci I, Sgherri G, Albano E, et al. Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann Gastroenterol. 2018;31[6]:639–48.
29. Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study. Aliment Pharmacol Ther. 2008;28[8]:1013–20.
30. Lovell RM, Ford AC. Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am J Gastroenterol. 2012;107[12]:1793–801; quiz 1802.
31. Pourhoseingholi A, Vahedi M, Pourhoseingholi MA, Ashtari S, Moghimi-Dehkordi B, Safaee A, et al. Irritable bowel syndrome, gastro-oesophageal reflux disease and dyspepsia: overlap analysis using loglinear models. Arab J Gastroenterol. 2012;13[1]:20–3.
32. Gerson LB, Kahrilas PJ, Fass R. Insights into gastroesophageal reflux disease-associated dyspeptic symptoms. Clin Gastroenterol Hepatol. 2011;9[10]:824–33.
33. Quigley EMM, Lacy BE. Overlap of functional dyspepsia and GERD – diagnostic and treatment implications. Nat Rev Gastroenterol Hepatol. 2013;10[3]:175–86.
34. Bor S, Mandiracioglu A, Kitapcioglu G, Caymaz-Bor C, Gilbert RJ. Gastroesophageal reflux disease in a low-income region in Turkey. Am J Gastroenterol. 2005;100[4]:759–65.
35. Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67[3]:430–40.
36. Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Changes in prevalence, incidence and spontaneous loss of gastro-oesophageal reflux symptoms: a prospective population-based cohort study, the HUNT study. Gut. 2012;61[10]:1390–7.
37. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32[6]:720–37.
38. Jonasson C, Wernersson B, Hoff DAL, Hatlebakk JG. Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013;37[5]:564–72.
39. Teruel Sánchez-Vegazo C, Faro Leal V, Muriel García A, Mañas Gallardo N. Sensitivity and specificity of the gastrointestinal short form questionnaire in diagnosis of gastroesophageal reflux disease. Rev Esp Enferm Dig. 2016;108[4]:174–80.
40. Zaika S, Paliy I, Chernobrovyi V, Ksenchyn OO. The study and comparative analysis of GerdQ and GSRS questionnaires on gastroesophageal reflux disease diagnostics. Prz Gastroenterol. 2020;15 [4]:323–9.
41. Dent J, Vakil N, Jones R, Bytzer P, Schöning U, Halling K, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut. 2010;59[6]:714–21.
42. Dong YY, Chen FX, Yu YB, Du C, Qi QQ, Liu H, et al. A school-based study with Rome III criteria on the prevalence of functional gastrointestinal disorders in Chinese college and university students. PLoS One. 2013;8[1]:e54183.

Article / Publication Details

First-Page Preview

Received: October 23, 2021
Accepted: July 24, 2022
Published online: August 16, 2022

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 1

ISSN: 0257-2753 [Print]
eISSN: 1421-9875 [Online]

For additional information: //www.karger.com/DDI

What is the epidemiology of GORD?

How many people are affected by acid reflux in the world?

How many people in the UK have GERD?

What causes GERD scholarly articles?